Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Lineage Cell Therapeutics (LCTX) Net Income towards Common Stockholders Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Lineage Cell Therapeutics | 251.15 Mn | 188.44 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.15% |
| Dec 31, 2025 | -51.25% |
| Sep 30, 2025 | -18.84% |
| Jun 30, 2025 | -28.11% |
| Mar 31, 2025 | 4.17% |
| Dec 31, 2024 | -18.89% |
| Sep 30, 2024 | 30.50% |
| Jun 30, 2024 | 29.23% |
| Mar 31, 2024 | -17.24% |
| Dec 31, 2023 | 36.41% |
| Sep 30, 2023 | -16.08% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | 41.39% |
| Dec 31, 2022 | 39.32% |
| Sep 30, 2022 | -18.37% |
| Jun 30, 2022 | 15.88% |
| Mar 31, 2022 | -16.43% |
| Dec 31, 2021 | -40.73% |
| Sep 30, 2021 | -17.62% |
| Jun 30, 2021 | -17.10% |